Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Several claims about St. John's wort, red yeast rice, garlic, ginkgo, and green tea are not supported by the provided label excerpts. Grapefruit juice dose/interaction details are partially supported. One claim about strong CYP3A4 inhibitors increasing atorvastatin exposure and myopathy risk is supported.
Category Scores
Accurate Statements
Concomitant administration of LIPITOR with strong CYP 3A4 inhibitors can lead to increases in plasma concentrations of atorvastatin, with extent dependent on CYP3A4 variability (includes examples clarithromycin, HIV protease inhibitors, itraconazole).
Label 7.1 Strong Inhibitors of CYP 3A4
In patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg.
Label 7.1 Strong Inhibitors of CYP 3A4
In patients taking HIV protease inhibitors, caution should be used when the LIPITOR dose exceeds 20 mg.
Label 7.1 Strong Inhibitors of CYP 3A4
In patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg.
Label 7.1 Strong Inhibitors of CYP 3A4
Concomitant use of higher doses of atorvastatin with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) increases risk of myopathy/rhabdomyolysis.
Label 5.1 Skeletal Muscle
Patients should be advised to report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.
Label 5.1 Skeletal Muscle
Patients taking LIPITOR should inform other healthcare professionals prescribing a new medication that they are taking LIPITOR.
Label 17 Patient Counseling Information
Unsupported Statements
Lipitor can interact with herbal remedies by affecting its metabolism via the CYP3A4 enzyme in the liver or altering cholesterol levels.
The provided label excerpts discuss specific drug–drug interactions and grapefruit/strong CYP3A4 inhibitors, but do not provide label-supported statements about 'herbal remedies' broadly or 'altering cholesterol levels' as a mechanism for interactions.
Herbal interactions that increase Lipitor blood levels may increase the risks of muscle pain, liver damage, or rhabdomyolysis.
The excerpts support increased myopathy/rhabdomyolysis risk with certain concomitant drugs (e.g., strong CYP3A4 inhibitors) but do not support generalized statements about 'herbal interactions' or liver damage as a labeled risk tied to those herbals.
St. John's wort strongly induces CYP3A4 and speeds up Lipitor breakdown.
No St. John's wort interaction content is present in the provided label excerpts.
St. John's wort reduces Lipitor effectiveness.
No St. John's wort interaction content is present in the provided label excerpts.
Patients on Lipitor should avoid St. John's wort to prevent treatment failure.
No St. John's wort avoidance guidance is present in the provided label excerpts.
Grapefruit juice boosts Lipitor levels up to 2-3 times.
The provided grapefruit juice section supports increased concentrations with excessive consumption but does not provide a '2-3 times' magnitude.
Limiting grapefruit juice to small amounts (under 1 quart daily) or avoiding it is recommended to manage the interaction.
The provided label specifies excessive grapefruit juice consumption (>1.2 liters per day) but does not provide guidance to 'under 1 quart' or a specific recommendation to limit 'small amounts' as an explicit management instruction.
The effects of grapefruit juice on Lipitor last 24+ hours after consumption.
No duration-after-consumption statement is present in the provided grapefruit juice excerpt.
Red yeast rice contains monacolin K, which is identical to lovastatin.
No red yeast rice/monacolin K content is present in the provided label excerpts.
Combining red yeast rice with Lipitor raises statin dose equivalent.
No red yeast rice content is present in the provided label excerpts.
Combining red yeast rice with Lipitor increases myopathy risk.
The label excerpt discusses myopathy risk with certain drugs (including higher doses with specific drugs) but does not provide red yeast rice-specific interaction content.
Red yeast rice should not be used together with Lipitor.
No red yeast rice-specific contraindication or avoidance statement is present in the provided label excerpts.
Garlic may mildly enhance Lipitor's blood-thinning effects, raising bleeding risk with antiplatelets.
No garlic/bleeding-risk interaction content is present in the provided label excerpts.
Ginkgo biloba inhibits platelet aggregation and may amplify bleeding risks when used with Lipitor.
No ginkgo/bleeding-risk interaction content is present in the provided label excerpts.
Green tea catechins weakly inhibit CYP3A4 and may increase Lipitor exposure.
No green tea interaction content is present in the provided label excerpts.
Evidence for the interactions with garlic, ginkgo, and green tea is limited.
No such interaction evidence statements appear in the provided label excerpts.
Patients should monitor for muscle symptoms if using these herbals with Lipitor.
The label supports monitoring/reporting muscle symptoms generally due to myopathy risk with interacting agents, but it does not support monitoring specifically for 'these herbals' (garlic/ginkgo/green tea/St. John's wort/red yeast rice).
Patients should consult a doctor before using these herbals with Lipitor.
No herbal-specific counseling instruction is present in the provided label excerpts.
Patients should inform doctors about herbal use before starting Lipitor.
The label excerpt advises patients to inform other healthcare professionals prescribing a new medication they are taking LIPITOR, but does not specifically state 'before starting' for 'herbal use.'
Herb–Lipitor interactions vary by dose, genetics, and health.
The excerpt notes extent depends on variability of effect on CYP3A4 for strong inhibitors, but does not support generalized 'herb–Lipitor interactions' variability by genetics/health.
Clinical data flags these herbal interactions via FDA warnings.
The provided label excerpts do not mention the referenced herbals (St. John's wort, red yeast rice, garlic, ginkgo, green tea) or any FDA warning language about them.
Contradictions
Important Omissions
For grapefruit juice, the label excerpt only specifies increased atorvastatin concentrations with excessive grapefruit juice consumption (>1.2 liters/day); the AI statements include an unsupported magnitude (2-3 times) and an unsupported specific limiting threshold (under 1 quart daily) and duration (24+ hours) rather than sticking to the label's stated threshold.
Importance:
Moderate
The label excerpt does not support generalized 'herbal remedies' interaction mechanisms; if addressing herbals, the response should be limited to interactions actually discussed (e.g., grapefruit juice and strong CYP3A4 inhibitors) or omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported herbal-specific interaction claims could lead to inappropriate avoidance or risk management beyond what the provided label supports. Supported sections regarding strong CYP3A4 inhibitors and myopathy monitoring are present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple herbal-specific interaction claims (St. John's wort, red yeast rice, garlic, ginkgo, green tea) are not supported by the provided Lipitor label excerpts; grapefruit juice details include unsupported quantitative and timing statements.
Suggested Improvement
Restrict interaction statements to what the label excerpt explicitly covers (e.g., grapefruit juice: increased concentrations with excessive intake >1.2 L/day; strong CYP3A4 inhibitors: increased atorvastatin concentrations and increased myopathy/rhabdomyolysis risk with dose-caution guidance). Remove or qualify unsupported herbal-specific claims unless supported by additional label sections.